If you’ve been debating starting a weight-loss treatment like tirzepatide or semaglutide, you’re going to want to listen ...

Ozempic maker Novo Nordisk says it has developed a compound that’s shown to be a one-two punch for appetite suppression and ...

More than half of Americans qualify for GLP-1 receptor agonist drugs, but many can't afford them. Experts share cheaper ...

Bone broth, which is having an inescapable resurgence, is rapidly increasing in popularity, and with good reason. Having ...

After struggling with weight gain for three years, Sarah Bisacca was diagnosed with insulin resistance. Here's how she was learned to manage it.

Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.

Participants in Wegovy clinical trials were more likely to report “severe gastrointestinal adverse reactions,” the FDA's ...

Millions of Americans with obesity would be eligible to have popular weight-loss drugs like Wegovy or Zepbound covered by ...

Lilly said patients taking Zepbound lost about 20% of their weight on average compared to nearly 14% for Wegovy.

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...

A new study is shedding light on which of two drugs currently approved by the U.S. Food and Drug Administration for weight ...

SURMOUNT-5’s results reflect those of multiple real-world studies, which have found that tirzepatide treatment results in ...